Literature DB >> 33774631

Fertility of Women Treated during Childhood with Triptorelin (Depot Formulation) for Central Precocious Puberty: The PREFER Study.

Laetitia Martinerie1,2, Jacques de Mouzon3, Joelle Blumberg4, Luigi di Nicola5, Pascal Maisonobe4, Jean-Claude Carel1,2.   

Abstract

BACKGROUND: Gonadotropin-releasing hormone analogues (GnRHa) administered as depot formulations are the standard of care for children with central precocious puberty (CPP). Puberty resumes after treatment discontinuation, but little is known concerning fertility in women who have been treated with GnRHa for CPP during childhood.
METHODS: The PREFER (PREcocious puberty, FERtility) study prospectively analysed fertility, via a series of questionnaires, in women treated during childhood with triptorelin (depot formulation) for CPP. Co-primary endpoints were the proportion of women wanting a pregnancy any time before study inclusion and during the follow-up period but not pregnant 6 and 12 months after stopping contraception and the waiting time to pregnancy (WTP).
RESULTS: A total of 574 women were identified, and 194 women were included in the analysis. Although there were not enough data for primary endpoint assessment, few women (1.7%) reported issues with fertility or were unable to become pregnant despite trying to conceive. Most pregnancies (84.4%, 95% CI [67.2-94.7%]) occurred within 1 year of trying to conceive, in line with the WTP for women without previous CPP.
CONCLUSION: The results, based on a limited sample of patients, suggest that CPP treated with triptorelin does not negatively impact women's fertility in adulthood. These results need to be consolidated with a subsequent study performed when these women will have reached their mid-thirties.
© 2021 S. Karger AG, Basel.

Entities:  

Keywords:  Fertility; Gonadotropin-releasing hormone analogue; Precocious puberty; Pregnancy; Triptorelin (depot formulation)

Mesh:

Substances:

Year:  2021        PMID: 33774631      PMCID: PMC8686727          DOI: 10.1159/000513702

Source DB:  PubMed          Journal:  Horm Res Paediatr        ISSN: 1663-2818            Impact factor:   2.852


  32 in total

Review 1.  MANAGEMENT OF ENDOCRINE DISEASE: Long-term outcomes of the treatment of central precocious puberty.

Authors:  Federica Guaraldi; Guglielmo Beccuti; Davide Gori; Lucia Ghizzoni
Journal:  Eur J Endocrinol       Date:  2015-10-14       Impact factor: 6.664

2.  International estimates of infertility prevalence and treatment-seeking: potential need and demand for infertility medical care.

Authors:  Jacky Boivin; Laura Bunting; John A Collins; Karl G Nygren
Journal:  Hum Reprod       Date:  2007-03-21       Impact factor: 6.918

3.  Moderate alcohol consumption and waiting time to pregnancy.

Authors:  M Juhl; A M Nyboe Andersen; M Grønbaek; J Olsen
Journal:  Hum Reprod       Date:  2001-12       Impact factor: 6.918

4.  Treatment of central precocious puberty with triptorelin 11.25 mg depot formulation.

Authors:  A Martínez-Aguayo; M I Hernández; F Beas; G Iñiguez; A Avila; H Sovino; E Bravo; F Cassorla
Journal:  J Pediatr Endocrinol Metab       Date:  2006-08       Impact factor: 1.634

Review 5.  Pharmacokinetics and pharmacodynamics of GnRH agonists: clinical implications in pediatrics.

Authors:  N Lahlou; J C Carel; J L Chaussain; M Roger
Journal:  J Pediatr Endocrinol Metab       Date:  2000-07       Impact factor: 1.634

6.  Effect of gonadotropin-releasing hormone agonist treatment in boys with central precocious puberty: final height results.

Authors:  D Mul; S Bertelloni; J C Carel; G Saggese; J L Chaussain; W Oostdijk
Journal:  Horm Res       Date:  2002

7.  The efficacy and safety of gonadotropin-releasing hormone analog treatment in childhood and adolescence: a single center, long-term follow-up study.

Authors:  Maria Alexandra Magiakou; Despoina Manousaki; Marina Papadaki; Dimitrios Hadjidakis; Georgia Levidou; Marina Vakaki; Athanassios Papaefstathiou; Niki Lalioti; Christina Kanaka-Gantenbein; George Piaditis; George P Chrousos; Catherine Dacou-Voutetakis
Journal:  J Clin Endocrinol Metab       Date:  2009-11-06       Impact factor: 5.958

8.  Time to pregnancy: results of the German prospective study and impact on the management of infertility.

Authors:  C Gnoth; D Godehardt; E Godehardt; P Frank-Herrmann; G Freundl
Journal:  Hum Reprod       Date:  2003-09       Impact factor: 6.918

9.  Treatment of central precocious puberty by subcutaneous injections of leuprorelin 3-month depot (11.25 mg).

Authors:  Jean-Claude Carel; Najiba Lahlou; Orlando Jaramillo; Vincent Montauban; Cécile Teinturier; Michel Colle; Christel Lucas; Jean Louis Chaussain
Journal:  J Clin Endocrinol Metab       Date:  2002-09       Impact factor: 5.958

Review 10.  Consensus statement on the use of gonadotropin-releasing hormone analogs in children.

Authors:  Jean-Claude Carel; Erica A Eugster; Alan Rogol; Lucia Ghizzoni; Mark R Palmert; Franco Antoniazzi; Sheri Berenbaum; Jean-Pierre Bourguignon; George P Chrousos; Joël Coste; Sheri Deal; Liat de Vries; Carol Foster; Sabine Heger; Jack Holland; Kirsi Jahnukainen; Anders Juul; Paul Kaplowitz; Najiba Lahlou; Mary M Lee; Peter Lee; Deborah P Merke; E Kirk Neely; Wilma Oostdijk; Moshe Phillip; Robert L Rosenfield; Dorothy Shulman; Dennis Styne; Maïthé Tauber; Jan M Wit
Journal:  Pediatrics       Date:  2009-03-30       Impact factor: 7.124

View more
  2 in total

Review 1.  Reproductive health risks and clinician practices with gender diverse adolescents and young adults.

Authors:  Gwendolyn P Quinn; Amy C Tishelman; Diane Chen; Leena Nahata
Journal:  Andrology       Date:  2021-05-24       Impact factor: 3.842

Review 2.  Gonadotropin-releasing hormone analog therapies for children with central precocious puberty in the United States.

Authors:  Jadranka Popovic; Mitchell E Geffner; Alan D Rogol; Lawrence A Silverman; Paul B Kaplowitz; Nelly Mauras; Philip Zeitler; Erica A Eugster; Karen O Klein
Journal:  Front Pediatr       Date:  2022-10-04       Impact factor: 3.569

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.